{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T04:02:39Z","timestamp":1784520159910,"version":"3.55.0"},"reference-count":50,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Venous thromboembolism (VTE) is labeled as an adverse effect of the adeno\u2010vector\u2010based vaccines AstraZeneca and Johnson &amp; Johnson. We aimed to study whether there was an increase in general practitioner (GP) consultations for VTE after COVID\u201019 vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An exposure\u2010anchored self\u2010controlled cohort study was performed among COVID\u201019 vaccinated persons aged \u2265\u200912\u2009years who were registered in the PHARMO Data Network and Nivel Primary Care Database in the Netherlands. The focal window was set at 28\u2009days after each COVID\u201019 vaccination and the referent window at all time outside the focal window. Adjusted incidence rate ratios (aIRR), adjusting for SARS\u2010CoV\u20102 infection, were calculated using Poisson regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 2\u2009133\u2009853 persons were included. The highest increase in GP consultations for VTE was observed after Johnson &amp; Johnson vaccination (aIRR: 3.14, 95% CI: 1.50\u20136.57), and a slight increase after Pfizer\/BioNTech dose 1 (aIRR: 1.24, 95% CI: 1.09\u20131.40). Risk groups were 12\u201360\u2009year\u2010olds with increased GP consultations for VTE after Johnson &amp; Johnson (aIRR: 2.30, 95% CI: 1.44\u20133.69) and Pfizer\/BioNTech (aIRR: 1.29, 95% CI: 1.11\u20131.50), and in specific groups of males aged 12\u201360\u2009years. Also, females using hormone\u2010containing contraceptives or hormone replacement therapy (HRT) showed increased GP consultations for VTE after AstraZeneca (aIRR: 2.87, 95% CI: 1.13\u20137.33) and Pfizer\/BioNTech (aIRR: 1.48, 95% CI: 1.10\u20132.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Increased GP consultations for VTE were observed after both vector and mRNA vaccination, in particular among males, 12\u201360\u2009year olds, and females using hormone\u2010containing contraceptives or HRT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pds.70317","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T01:00:30Z","timestamp":1767574830000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["<scp>GP<\/scp>\n                    Consultations for Venous Thromboembolism (\n                    <scp>VTE<\/scp>\n                    ) After\n                    <scp>mRNA<\/scp>\n                    and Adeno\u2010Vector\u2010Based\n                    <scp>COVID<\/scp>\n                    \u201019 Vaccination\u2014An Exposure\u2010Anchored Self\u2010Controlled Cohort Study Based on Primary Healthcare Data From the Netherlands"],"prefix":"10.1002","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5957-5261","authenticated-orcid":false,"given":"R.","family":"Jajou","sequence":"first","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb  's\u2010Hertogenbosch the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2236-1398","authenticated-orcid":false,"given":"E. P.","family":"van Puijenbroek","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb  's\u2010Hertogenbosch the Netherlands"},{"name":"Department of PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy (GRIP) University of Groningen  Groningen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9551-1564","authenticated-orcid":false,"given":"K.","family":"Hek","sequence":"additional","affiliation":[{"name":"Nivel (Netherlands Institute for Health Services Research)  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0935-5193","authenticated-orcid":false,"given":"J. A.","family":"Overbeek","sequence":"additional","affiliation":[{"name":"PHARMO Institute for Drug Outcomes Research  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8965-3224","authenticated-orcid":false,"given":"F. P. A. M.","family":"van Hunsel","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb  's\u2010Hertogenbosch the Netherlands"},{"name":"Department of PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy (GRIP) University of Groningen  Groningen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Mulder","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb  's\u2010Hertogenbosch the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3767-110X","authenticated-orcid":false,"given":"A. C.","family":"Kant","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb  's\u2010Hertogenbosch the Netherlands"},{"name":"Department of Clinical Pharmacy and Toxicology Leiden University Medical Center  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,4]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"Centers for Disease Control and Prevention (CDC) \u201cAbout Venous Thromboembolism (Blood Clots) \u201d2024 https:\/\/www.cdc.gov\/blood\u2010clots\/about\/index.html."},{"key":"e_1_2_8_3_1","unstructured":"National Heart Lung and Blood Institute \u201cWhat Is Venous Thromboembolism? \u201d2022 https:\/\/www.nhlbi.nih.gov\/health\/venous\u2010thromboembolism."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043169"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1931"},{"key":"e_1_2_8_6_1","article-title":"Arterial Events, Venous Thromboembolism, Thrombocytopenia, and Bleeding After Vaccination With Oxford\u2010AstraZeneca ChAdOx1\u2010S in Denmark and Norway: Population Based Cohort Study","volume":"373","author":"Pottegard A.","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01408-4"},{"key":"e_1_2_8_8_1","unstructured":"European Medicines Agency (EMA) \u201cJcovden: EPAR\u2014Product Information \u201d2024."},{"key":"e_1_2_8_9_1","unstructured":"European Medicines Agency (EMA) \u201cVaxzevria: EPAR\u2014Product Information \u201d2024."},{"key":"e_1_2_8_10_1","unstructured":"European Medicines Agency (EMA) \u201cVaxzevria1 (COVID 19 Vaccine (ChAdOx1 S [recombinant]))\u2014Withdrawal of the Marketing Authorisation in the European Union \u201d2024."},{"key":"e_1_2_8_11_1","unstructured":"European Medicines Agency (EMA) \u201cJcovden (Previously COVID\u201019 Vaccine Janssen) \u201d2024."},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47486-x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34668-w"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34669-9"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.01.100"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.7326\/M22-0988"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2022.527"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101504"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20118-6"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110475"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.15072"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32264-6"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.7326\/M21-2452"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.17375"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081317"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071594"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100970"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2022.12.012"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100260"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49634-x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003926"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S247575"},{"key":"e_1_2_8_33_1","unstructured":"Nivel \u201cZorg door de huisarts: jaarcijfers 2022 en trendcijfers 2018\u20132022 \u201d2023."},{"key":"e_1_2_8_34_1","unstructured":"RIVM \u201cVaccination Registration by RIVM and Your Privacy \u201d2024."},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70071"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5227"},{"key":"e_1_2_8_37_1","unstructured":"European Medicines Agency (EMA) \u201cComirnaty: EPAR\u2014Product Information \u201d2024."},{"key":"e_1_2_8_38_1","unstructured":"European Medicines Agency (EMA) \u201cSpikevax: EPAR\u2014Product Information \u201d2024."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.neo.7900263"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2021.0213"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.732855"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012669"},{"key":"e_1_2_8_43_1","article-title":"Covid\u201019: European Countries Suspend Use of Oxford\u2010AstraZeneca Vaccine After Reports of Blood Clots","volume":"372","author":"Wise J.","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"e_1_2_8_44_1","unstructured":"European Medicines Agency (EMA) \u201cCOVID\u201019 Vaccine Janssen: EMA Finds Possible Link to Very Rare Cases of Unusual Blood Clots With Low Blood Platelets 2021 [Updated 21\u201004\u20102021 18\u201008\u20102021] \u201dhttps:\/\/www.ema.europa.eu\/en\/news\/covid\u201019\u2010vaccine\u2010janssen\u2010ema\u2010finds\u2010possible\u2010link\u2010very\u2010rare\u2010cases\u2010unusual\u2010blood\u2010clots\u2010low\u2010blood\u2010platelets."},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S389598"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e32832d867a"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/0268355519897650"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.04.037"},{"key":"e_1_2_8_49_1","volume-title":"Percentage gevaccineerden dat data wil delen met RIVM daalt onder de kritische grens van 95 procent","author":"Huisman C.","year":"2021"},{"key":"e_1_2_8_50_1","unstructured":"G. J.Geersing L. S.Kessel J. M.Poldervaart et\u00a0al. \u201cNHG\u2010Standaard M86 Diepveneuze trombose en longembolie 2023 [Updated 09\u20102024] \u201dhttps:\/\/richtlijnen.nhg.org\/standaarden\/diepveneuze\u2010trombose\u2010en\u2010longembolie."},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwae141"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70317","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.70317","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T03:23:22Z","timestamp":1784517802000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/pds.70317"],"URL":"https:\/\/doi.org\/10.1002\/pds.70317","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70317"}}